Abstract
People with HIV (PWH) and people with diabetes mellitus have increased risk of severe COVID-19, but little is known about humoral response to COVID-19 vaccines in PWH with DM. We investigated SARS-CoV-2 antireceptor-binding domain (anti-RBD) immunoglobulin G (IgG) geometrical concentrations and neutralizing antibody capacity (nAB) in PWH with and without diabetes mellitus. Anti-RBD IgG and nAB in COVID-19-vaccinated PWH were not associated with diabetes mellitus-status or HbA1c 24 months after the initial COVID-19 vaccination.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
MeSH terms
-
Adult
-
Aged
-
Antibodies, Neutralizing* / blood
-
Antibodies, Neutralizing* / immunology
-
Antibodies, Viral* / blood
-
COVID-19 Vaccines* / administration & dosage
-
COVID-19 Vaccines* / immunology
-
COVID-19* / complications
-
COVID-19* / immunology
-
COVID-19* / prevention & control
-
Diabetes Mellitus / immunology
-
Female
-
HIV Infections* / complications
-
HIV Infections* / immunology
-
Humans
-
Immunity, Humoral*
-
Immunoglobulin G* / blood
-
Immunoglobulin G* / immunology
-
Male
-
Middle Aged
-
SARS-CoV-2* / immunology
-
Vaccination
Substances
-
COVID-19 Vaccines
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
Immunoglobulin G